Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 14

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 14
---
 credit ratings will remain in effect for any given period of time or that such ratings will not be lowered, suspended or withdrawn entirely by the rating agencies, if, in each rating agency’s judgment, circumstances so warrant. A downgrade or potential downgrade in our credit ratings or the assignment of new ratings that are lower than existing ratings could reduce the population of potential investors in the Notes and adversely affect the price and liquidity of the Notes. A rating is based upon information furnished by us or obtained by the rating agency from its own sources and is subject to revision, suspension or withdrawal by the rating agency at any time. We have no obligation to inform holders of the Notes of any such revision, suspension or withdrawal.

The market for the Notes may have limited liquidity.

The Notes are a new issuance of securities for which no public trading market currently exists. The Notes will not be quoted on any automated dealer quotation system. The underwriters have informed us that they currently intend to make a market in each series of the Notes following this offering. However, they have no obligation to do so and may stop at any time. Furthermore, there can be no assurance as to the liquidity of any markets that may develop for the Notes or the prices at which you will be able to sell your Notes, if at all. Future trading prices of the Notes will depend on many factors, including:

• prevailing interest rates;

• our financial condition and results of operations;

• the then-current ratings assigned to the Notes;

<div align='center'>S-8</div>

• the market for similar securities; and

• general economic conditions.

Any trading markets that develop would be affected by many factors independent of and in addition to the foregoing, including the time remaining to the maturity of the Notes, the outstanding amount of the Notes and the level, direction and volatility of market interest rates generally.

<div align='center'>S-9</div>

### USE OF PROCEEDS
TUSFI expects to receive a total of approximately $ million in net proceeds from this offering, after deducting underwriting discounts and estimated offering expenses payable by TUSFI. TUSFI intends to remit the net proceeds from the offering of the Notes via intercompany loans and intercompany dividends to TPC. TPC intends to use such proceeds primarily to pay down its short-term borrowings such as certain of its outstanding commercial paper and the $500.0 million short-term loan originally incurred to pre-pay its then outstanding long-term borrowings in the fiscal year ended March 31, 2025.

As